Delving into the Latest Updates on Xiamen LP Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Contrast agent

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	11
Endocrinology and Metabolic Disease	4
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	16
Contrast agent	1

Top 5 Target	Count

ADRA2(Adrenergic receptors alpha-2)	1
NET x SERT	1
5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor	1
GABA transaminase(Gamma-amino-N-butyrate transaminase)	1
KATP channels	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

6

2

Phase 1 Clinical

Phase 2 Clinical

1

3

Phase 3 Clinical

NDA/BLA

1

4

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Perfluoropropane-albumin Microspheres (Lizhuo Pharma)	Contrast agents More	Approved
Pramipexole Dihydrochloride ( D2 receptor x D3 receptor )	Parkinson Disease More	Approved
Aripiprazole ( 5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor )	Schizophrenia More	Approved
Clonidine Hydrochloride ( ADRA2 )	Attention Deficit Disorder With Hyperactivity More	Approved
Donepezil Hydrochloride ( AChE )	-	NDA/BLA